Beta Thalassemia clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
open to eligible people ages 6 months to 34 years
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell …
Los Angeles, California and other locations
Our lead scientists for Beta Thalassemia research studies include Theodore B Moore, MD.
Last updated: